Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Shareholder Meeting (September 2016)
16 slides from Viyash Scientific's shareholder meeting presentation, Sep 23, 2016
Slide 1: Designed for Growth, Built for Value - 31st AGM
Seauent Proven Ability In Life Sciences DESIGNED FOR GROWTH BUILT FOR VALUE WARM WELCOME TO SHAREHOLDERS 318T ANNUAL GENERAL MEETING 238P SEPTEMBER 2016
Slide 2: Sequence of Events
SeQuent of Events Sequent = YEAR AT A GLANCE =" FINANCIAL SNAPSHOT-FY16 = KEY INITIATIVES-FY17 = POST BALANCE SHEET EVENTS = AGENDA GOH e
Slide 3: Year at a Glance
Sequent YEAR AT A GLANCE OOH > ]
Slide 4: Year at a glance
Year at a glance Operations Corporate Initiatives Financials Fully operationalized state-of- New strategy facilitated Operating revenue at Rs. 6,345 the-art Vizag facility (Veterinary through five inorganic mn, as compared to Rs. 4,432 in APIs) expansions for enhancing scale, FY 16, up by 43%
Slide 5: Strategic Progress
Strategic Progress Human APIs Alivira Naari Robust growth of 77% over Doubled our business in India Forayed into Women healthcare previous year through Lyka acquisition segment with acquisition of Number 3 Animal Health controlling stake in Naari (Indo Regulated business now accounts compa
Slide 6: Performance FY16
Sequent PERFORMANCE FY16 GOR eo
Slide 7: Abstract from Consolidated P&L Account
Abstract from Consolidated P&L Account INR million PARTICULARS FY15 FY16 Revenue from Operations 4,654 6,345 Material Consumption 2,411 3,146 Operating Expenses 2,037 2,570 EBITDA 206 629 % 4.4% 10.0% Finance Cost (445) (386) Profit before Exceptional Items (469) (133) Exceptional Items 385 (37) Tax
Slide 8: Consolidated Balance Sheet
Consolidated Balance Sheet INR million PARTICULARS FY15 FY16 LIABILITIES Equity and Reserves 625 8,603 Share Application Money 288 131 Borrowings 4,546 2,687 Minority Interest 1,469 257 Provisions/Other Liabilities 2,149 2,329 TOTAL 9,077 14,007 ASSETS Fixed Assets 4,424 5,173 Investments 586 1,799
Slide 9: Strengthened Balance sheet
Strengthened Balance sheet Gross Block & CWIP (INR mn) Total Debt (INR mn) 4,546 6,974 3,777 5,642 2,898 2,687 4,100 4,027 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 Current Ratio (x) Debt to Equity (x) 9.80 1.71 5.00 0.76 0.30 0.67 3.10 0.65 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 Investment to acquir
Slide 10: Business Performance
Business Performance Net Sales (INR mn) Net Loss (INR mn) FY13 FY14 FY15 FY16 -222 -107 -647 -492 -1,105 6,345 4,654 4,555 3,269 FY13 FY14 FY15 FY16 EBITDA* (INR mn) Cash from Operations (INR mn) FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 -1 -38 -235 -448 629 -133 79 206 Strong focus on execution leadi
Slide 11: Market Capitalization
Market Capitalization Stock Price Movement 742.5 * 512 * 190 69 130 Mar 31, 2012 Mar 31, 2013 Mar 31, 2014 Mar 31, 2015 Mar 31, 2016 Market Cap (INR mn) 35,426 * 15,596 5,194 1,514 3,125 Mar 31, 2012 Mar 31, 2013 Mar 31, 2014 Mar 31, 2015 Mar 31, 2016 * Actual market price adjusted to reflect stock
Slide 12: Shareholding
Shareholding Others, 22.7% Promoters, FIIs/FPIs, 57.2% 13.8% DIIs/MFs, 6.2% 12 On fully diluted basis
Slide 13: Post Balance Sheet events
Post Balance Sheet events Performance Q1FY17 Business Events Operating revenue was Rs 1768 mn as Karizoo Spain acquisition closed on 30th compared to Rs 1461 mn in Q1FY16, up by June and Interchange Brazil on 29th July 21% Emerging Markets Formulation business EBITDA at Rs 92 mn as compared
Slide 14: Agenda for AGM
Sequent AGENDA FOR AGM em’ VaBRY GOR ]
Slide 15: Agenda for AGM
Agenda for AGM Adoption of Financial Statements for FY16 Appointment of Director in place of retiring Director Ratification of appointment of statutory auditors Appointment of Dr.S Devendra Kumar as a Non Executive Director Appointment of Mr. K E C Rajakumar as a Non Executive Director R
Slide 16: Thank you
Sequent Thank you
SeQuent Scientific — Shareholder Meeting (September 2016) on 6ix